MCID: ORL012
MIFTS: 48

Oral Leukoplakia

Categories: Oral diseases, Rare diseases

Aliases & Classifications for Oral Leukoplakia

MalaCards integrated aliases for Oral Leukoplakia:

Name: Oral Leukoplakia 54 30
Leukoplakia, Oral 74
Leukoplakia Oral 56

Classifications:



External Ids:

UMLS 74 C0023532

Summaries for Oral Leukoplakia

NIH Rare Diseases : 54 Oral leukoplakia describes a white plaque that does not rub off and cannot be characterized as any other condition. Though it may occur in any part of the mouth, it generally affects the tongue, gums, and inner cheek. Physicians will usually biopsy oral leukoplakia lesions as 20-40% of cases are precancerous or cancerous at the time of biopsy and another 8-15% become cancerous over time. The exact cause of oral leukoplakia is not known. Factors that may increase the risk of developing oral leukoplakia include smoking, alcohol use, vitamin deficiencies, malocclusion, and a weakened immune system.Treatment depends on the biopsy results and the size, appearance, and location of the oral leukoplakia. Removal or ablation of the lesion by surgery, laser, or cryotherapy (use of low temperature) may be recommended.

MalaCards based summary : Oral Leukoplakia, also known as leukoplakia, oral, is related to leukoplakia and verrucous carcinoma. An important gene associated with Oral Leukoplakia is GSTM1 (Glutathione S-Transferase Mu 1), and among its related pathways/superpathways are Cell Cycle, Mitotic and Human cytomegalovirus infection. The drugs Rosiglitazone and Pioglitazone have been mentioned in the context of this disorder. Affiliated tissues include tongue, testes and liver, and related phenotypes are Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Related Diseases for Oral Leukoplakia

Diseases related to Oral Leukoplakia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 178)
# Related Disease Score Top Affiliating Genes
1 leukoplakia 31.6 GSTM1 MKI67 PCNA
2 verrucous carcinoma 29.9 CCND1 CDKN2A TP53
3 in situ carcinoma 29.9 CDKN2A TP53
4 squamous cell carcinoma 29.8 CCND1 CDKN2A MKI67 TP53 TP63 XRCC1
5 esophageal cancer 29.7 CCND1 CDKN2A GSTM1 TP53
6 oral cancer 29.5 CCND1 CDKN2A GSTM1 PCNA TP53
7 papilloma 29.1 CCND1 CDKN2A PCNA TP53 TP63
8 proliferative verrucous leukoplakia 12.0
9 oral hairy leukoplakia 11.8
10 dyskeratosis congenita 11.6
11 revesz syndrome 11.3
12 oral mucosa leukoplakia 11.3
13 dyskeratosis congenita, autosomal recessive 5 11.2
14 dyskeratosis congenita, autosomal recessive 6 11.2
15 dyskeratosis congenita, autosomal dominant 6 11.2
16 oral squamous cell carcinoma 10.7
17 lichen planus 10.5
18 oral submucous fibrosis 10.4
19 oral lichen planus 10.4
20 brain ependymoma 10.3 MKI67 TP53
21 bladder squamous cell carcinoma 10.3 CDKN2A TP53
22 keratinizing squamous cell carcinoma 10.3 CDKN2A TP53
23 bladder carcinoma in situ 10.3 CDKN2A TP53
24 vulva squamous cell carcinoma 10.3 CDKN2A TP53
25 scrotal carcinoma 10.3 CDKN2A TP53
26 adenosarcoma 10.3 MKI67 TP53
27 thyroid lymphoma 10.3 CDKN2A TP53
28 vulvar disease 10.3 CDKN2A TP53
29 nasal cavity adenocarcinoma 10.3 CDKN2A TP53
30 bartholin's gland disease 10.3 CDKN2A TP53
31 soft tissue sarcoma 10.3 MKI67 TP53
32 anal squamous cell carcinoma 10.3 CDKN2A TP53
33 megaesophagus 10.3 CDKN2A TP53
34 glycogen-rich clear cell breast carcinoma 10.3 CDKN2A TP53
35 gastric adenosquamous carcinoma 10.3 CDKN2A TP53
36 anogenital venereal wart 10.2 CDKN2A TP53
37 cervix uteri carcinoma in situ 10.2 CDKN2A TP53
38 uterus carcinoma in situ 10.2 CDKN2A TP53
39 meningeal melanomatosis 10.2 CDKN2A TP53
40 embryonal sarcoma 10.2 MKI67 TP53
41 endometrial mucinous adenocarcinoma 10.2 CDKN2A MKI67
42 dedifferentiated liposarcoma 10.2 CDKN2A TP53
43 endocervical adenocarcinoma 10.2 CDKN2A TP53
44 sister chromatid exchange, frequency of 10.2 GSTM1 XRCC1
45 penile disease 10.2 CDKN2A TP53
46 cervix small cell carcinoma 10.2 CDKN2A TP53
47 isolated cleft lip 10.2 GSTM1 TP63
48 basaloid squamous cell carcinoma 10.2 CDKN2A TP53
49 tongue disease 10.2 CDKN2A TP53
50 optic nerve neoplasm 10.2 CDKN2A TP53

Graphical network of the top 20 diseases related to Oral Leukoplakia:



Diseases related to Oral Leukoplakia

Symptoms & Phenotypes for Oral Leukoplakia

GenomeRNAi Phenotypes related to Oral Leukoplakia according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) GR00104-A-0 9.33 CCND1 MKI67 PCNA
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.32 CDKN2A PCNA TP53 XRCC1
3 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.32 CCND1 CDKN2A PCNA TP53 TP63 XRCC1
4 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.26 PCNA TP53 TP63 XRCC1

MGI Mouse Phenotypes related to Oral Leukoplakia:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 9.87 CCND1 CDKN2A PCNA TINF2 TP53 TP63
2 endocrine/exocrine gland MP:0005379 9.85 CCND1 CDKN2A PCNA TINF2 TP53 TP63
3 neoplasm MP:0002006 9.65 CCND1 CDKN2A TP53 TP63 XRCC1
4 no phenotypic analysis MP:0003012 9.63 CDKN2A MKI67 PCNA TINF2 TP53 TP63
5 normal MP:0002873 9.43 CCND1 MKI67 TINF2 TP53 TP63 XRCC1
6 reproductive system MP:0005389 9.1 CCND1 CDKN2A PCNA TINF2 TP53 TP63

Drugs & Therapeutics for Oral Leukoplakia

Drugs for Oral Leukoplakia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 56)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Rosiglitazone Approved, Investigational Phase 2 122320-73-4 77999
2
Pioglitazone Approved, Investigational Phase 2 111025-46-8 4829
3
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
4
Aminolevulinic acid Approved Phase 1, Phase 2 106-60-5 137
5
Trioxsalen Approved Phase 2 3902-71-4 5585
6
nivolumab Approved Phase 2 946414-94-4
7
Metformin Approved Phase 2 657-24-9 14219 4091
8
Pembrolizumab Approved Phase 2 1374853-91-4
9
SB-649868 Experimental, Investigational Phase 2 110-16-7, 110-17-8 444972
10
Fenretinide Investigational Phase 2 65646-68-6
11 Hypoglycemic Agents Phase 2
12 Analgesics Phase 2,Phase 1,Not Applicable
13 Antirheumatic Agents Phase 2,Phase 1,Not Applicable
14 Analgesics, Non-Narcotic Phase 2,Phase 1,Not Applicable
15 Peripheral Nervous System Agents Phase 2,Phase 1,Not Applicable
16 Anti-Inflammatory Agents Phase 2,Phase 1,Not Applicable
17 Anti-Inflammatory Agents, Non-Steroidal Phase 2,Phase 1,Not Applicable
18 Cyclooxygenase 2 Inhibitors Phase 2
19 Cyclooxygenase Inhibitors Phase 2,Phase 1,Not Applicable
20 Retinamide Phase 2
21 Pharmaceutical Solutions Phase 1, Phase 2
22 Photosensitizing Agents Phase 1, Phase 2,Phase 2
23 Dermatologic Agents Phase 1, Phase 2,Phase 2
24 Hematoporphyrin Derivative Phase 2
25 Dihematoporphyrin Ether Phase 2
26 Ether Phase 2
27 Hematoporphyrins Phase 2
28 Antineoplastic Agents, Immunological Phase 2
29 Tea Phase 2
30
Aspirin Approved, Vet_approved Phase 1 50-78-2 2244
31 Fibrinolytic Agents Phase 1
32 Antipyretics Phase 1
33 Platelet Aggregation Inhibitors Phase 1
34
Heparin Approved, Investigational 9005-49-6 772 46507594
35
Acyclovir Approved Not Applicable 59277-89-3 2022
36
leucovorin Approved Not Applicable 58-05-9 6006 143
37
Dapsone Approved, Investigational Not Applicable 80-08-0 2955
38
Sulindac Approved, Investigational Not Applicable 38194-50-2 1548887 5352
39
Ethanol Approved 64-17-5 702
40
Folic Acid Approved, Nutraceutical, Vet_approved Not Applicable 59-30-3 6037
41 Antioxidants
42 Protective Agents
43 Hemostatics ,Not Applicable
44 Tolonium Chloride
45 calcium heparin
46 Coagulants
47 Antiviral Agents Not Applicable
48 Anti-Infective Agents Not Applicable
49 Antiprotozoal Agents Not Applicable
50 Folic Acid Antagonists Not Applicable

Interventional clinical trials:

(show all 30)
# Name Status NCT ID Phase Drugs
1 Photodynamic Therapy for Oral Leukoplakia and Erythroleukoplakia Completed NCT00155337 Phase 4
2 Rosiglitazone Maleate in Treating Patients With Oral Leukoplakia Completed NCT00369174 Phase 2 rosiglitazone maleate
3 Pioglitazone Hydrochloride in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia Completed NCT00099021 Phase 2 pioglitazone hydrochloride
4 Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Patients With Oral Leukoplakia Completed NCT00330382 Phase 2 Bowman-Birk inhibitor concentrate
5 Celecoxib in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia Completed NCT00101335 Phase 2 celecoxib
6 Fenretinide in Treating Patients With Leukoplakia of the Mouth Completed NCT00004161 Phase 2 fenretinide;Placebo
7 Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia Completed NCT00052611 Phase 2 Celecoxib
8 Treatment of Oral Premalignant Lesions With 5-ALA PDT Completed NCT00571974 Phase 1, Phase 2 5-Aminolevulinic Acid (Levulan KerastickTM)
9 Photodynamic Therapy With Porfimer Sodium in Treating Patients With Precancerous Lesions, Cancer, or Other Disease of the Aerodigestive Tract Completed NCT00453336 Phase 2 Porfimer Sodium
10 Safety and Efficacy of Nivolumab in Treating Oral Proliferative Verrucous Leukoplakia Recruiting NCT03692325 Phase 2 Nivolumab
11 Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion Active, not recruiting NCT02581137 Phase 2 Metformin Hydrochloride
12 Pembrolizumab in Treating Participants With Leukoplakia Not yet recruiting NCT03603223 Phase 2
13 A Phase II Trial to Assess the Effects of Green Tea in Oral Leukoplakia Terminated NCT00176566 Phase 2 Lozenge Intake
14 Pioglitazone for Oral Premalignant Lesions Terminated NCT00951379 Phase 2 Pioglitazone hydrochloride
15 Aspirin Mouthwash in Treating Patients With Oral Leukoplakia Completed NCT01238185 Phase 1 acetylsalicylic acid
16 Photodynamic Therapy Using Aminolevulinic Acid in Treating Patients With Oral Leukoplakia Terminated NCT00571558 Phase 1 aminolevulinic acid hydrochloride;photodynamic therapy
17 Least Invasive Nonlinear Light Microscopy Unknown status NCT00767442
18 Infectious Aetiology of Potentially Malignant Disorders and Squamous Cell Carcinomas of the Oral Cavity Unknown status NCT01636544 Not Applicable
19 Comparison Between Two Different High Power Ablative Lasers in the Treatment of Oral Leukoplakia Completed NCT03233165 Not Applicable
20 Biomarkers for Oral Cancer Completed NCT00341497
21 8-Hydroxy-2-Deoxyguanosine ,Total Antioxidant Capacity in Oral Premalignant and Malignant Lesions Completed NCT03830710
22 Comparison or Rose Bengal and Toluidine Blue Staining for Lesion Detection Efficacy Completed NCT03031899
23 Clinical Research Core Dental Screening Protocol Completed NCT00090818
24 Methylation of p16 CpG Island And Malignant Transformation of Oral Epithelial Dysplasia Completed NCT00835341
25 Treatment and Suppression of Hairy Leukoplakia in ARC Patients With Oral Acyclovir (ACV) Completed NCT00002026 Not Applicable Acyclovir
26 Dapsone 100 Mg Versus 50 as Primary Prophylaxis for Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS-Related Complex (ARC) Completed NCT00002043 Not Applicable Dapsone
27 Clinical Evaluation of the OncAlert RAPID in Subjects Presenting for Evaluation and/or Initial Biopsy; Impact on Decision-Making Recruiting NCT03239834
28 A Single Center Randomized Controlled Trial Assessing Pain and Quality of Life Following Surgery Active, not recruiting NCT01355926 Not Applicable
29 A Randomized Study of Sulindac in Oral Premalignant Lesions Active, not recruiting NCT00299195 Not Applicable sulindac;Placebo
30 Diagnostic Accuracy of Salivary DNA Integrity Index in Oral Malignant and Premalignant Lesions Not yet recruiting NCT03682562

Search NIH Clinical Center for Oral Leukoplakia

Genetic Tests for Oral Leukoplakia

Genetic tests related to Oral Leukoplakia:

# Genetic test Affiliating Genes
1 Oral Leukoplakia 30

Anatomical Context for Oral Leukoplakia

MalaCards organs/tissues related to Oral Leukoplakia:

42
Tongue, Testes, Liver, T Cells, Colon, Breast

Publications for Oral Leukoplakia

Articles related to Oral Leukoplakia:

(show top 50) (show all 571)
# Title Authors Year
1
Malignant transformation of oral leukoplakia treated with carbon dioxide laser: a meta-analysis. ( 30443884 )
2019
2
Podoplanin expression in oral leukoplakia─a prospective study. ( 30638740 )
2019
3
Nail dystrophy and oral leukoplakia in a 3-year-old girl. ( 30675941 )
2019
4
Evaluation of salivary metabolomics in oral leukoplakia and oral squamous cell carcinoma. ( 30714209 )
2019
5
Combined Testing of p16 Tumour-suppressor Protein and Human Papillomavirus in Patients With Oral Leukoplakia and Oral Squamous Cell Carcinoma. ( 30842161 )
2019
6
Evaluation of enzymatic and non-enzymatic antioxidant status and biomarkers of oxidative stress in saliva of patients with oral squamous cell carcinoma and oral leukoplakia: a pilot study. ( 30857448 )
2019
7
Determination and diagnostic value of CA9 mRNA in peripheral blood of patients with oral leukoplakia. ( 29745265 )
2018
8
Expression and oncogenic properties of membranous Notch1 in oral leukoplakia and oral squamous cell carcinoma. ( 29620248 )
2018
9
CD47 as a potential prognostic marker for oral leukoplakia and oral squamous cell carcinoma. ( 29805639 )
2018
10
A clinical diagnosis of oral leukoplakia; A guide for dentists. ( 29274164 )
2018
11
Immunoexpression of SOX-2 in oral leukoplakia. ( 29938872 )
2018
12
Knowledge about oral leukoplakia for use at different levels of expertise, including patients. ( 29480645 )
2018
13
Liquid-based oral brush cytology in the diagnosis of oral leukoplakia using a modified Bethesda Cytology system. ( 29957892 )
2018
14
Oral leukoplakia remains a challenging condition. ( 29480606 )
2018
15
T cells are involved in the induction of macrophage phenotypes in oral leukoplakia and squamous cell carcinoma-a preliminary report. ( 29108105 )
2018
16
Malignant transformation of Taiwanese patients with oral leukoplakia: A nationwide population-based retrospective cohort study. ( 29428194 )
2018
17
Podoplanin expression as a predictive marker of dysplasia in oral leukoplakia. ( 29588189 )
2018
18
Expression of DNA doublestrand repair proteins in oral leukoplakia and the risk of malignant transformation. ( 29928356 )
2018
19
Oral leukoplakia, a precancerous lesion of squamous cell carcinoma, in patients with long-term pegylated liposomal doxorubicin treatment. ( 29443777 )
2018
20
Secretory leukocyte peptidase inhibitor expression and apoptosis effect in oral leukoplakia and oral squamous cell carcinoma. ( 29436667 )
2018
21
Mature dendritic cell density is affected by smoking habit, lesion size, and epithelial dysplasia in oral leukoplakia samples. ( 30056280 )
2018
22
Low level laser therapy reduces oral leukoplakia lesion size: Results from a preliminary study. ( 30098877 )
2018
23
Effect of TP53 rs1042522 on the susceptibility of patients to oral squamous cell carcinoma and oral leukoplakia: a meta-analysis. ( 30126398 )
2018
24
CD8+ and CD163+ infiltrating cells and PD-L1 immunoexpression in oral leukoplakia and oral carcinoma. ( 30160018 )
2018
25
Transglutaminase 3 contributes to malignant transformation of oral leukoplakia to cancer. ( 30172723 )
2018
26
Oral leukoplakia: A diagnostic challenge for clinicians and pathologists. ( 30203899 )
2018
27
A three miRNAs signature for predicting the transformation of oral leukoplakia to oral squamous cell carcinoma. ( 30210912 )
2018
28
Treatment Outcome of Oral Leukoplakia with Er:YAG Laser: A 5-Year Follow-Up Prospective Comparative Study. ( 30339489 )
2018
29
Photodynamic therapy in the treatment of oral leukoplakia: a systematic review. ( 30391342 )
2018
30
Prevention of Malignant Transformation of Oral Leukoplakia and Oral Lichen Planus Using Laser: An Observational Study ( 30583693 )
2018
31
Expression of P53 Protein and Ki-67 Antigen in Oral Leukoplakia with Different Histopathological Grades of Epithelial Dysplasia. ( 30596042 )
2018
32
Detection of salivary heat shock protein 27 by enzyme-linked immunosorbent assay and its correlation with histopathology of oral leukoplakia. ( 30651672 )
2018
33
Primary Clinical Evaluation of Photodynamic Therapy With Oral Leukoplakia in Chinese Patients. ( 30723421 )
2018
34
Malignant transformation of oral leukoplakia in a patient with dyskeratosis congenita. ( 28923296 )
2017
35
Expression of Human Papillomavirus DNA and p53 Polymorphisms through Polymerase Chain Reaction in Normal Mucosa and Oral Leukoplakia Individuals with Deleterious Oral Habits. ( 28584747 )
2017
36
Correlation of Vascularization and Inflammation with Severity of Oral Leukoplakia. ( 29531547 )
2017
37
Different Expression of Aldehyde Dehydrogenases 1A1 and 2 in Oral Leukoplakia With Epithelial Dysplasia and in Oral Squamous Cell Carcinoma. ( 29189260 )
2017
38
In silico analysis of pathways activation landscape in oral squamous cell carcinoma and oral leukoplakia. ( 28580171 )
2017
39
Plasma HPV DNA is detectable in oral leukoplakia patients. ( 28554767 )
2017
40
Oral leukoplakia and proliferative verrucous leukoplakia: a review for dental practitioners. ( 29097794 )
2017
41
Nomogram for risk prediction of malignant transformation in oral leukoplakia patients using combined biomarkers. ( 28797449 )
2017
42
Evaluation of Genetic Polymorphisms in Glutathione S-Transferase Theta1, Glutathione S-Transferase Mu1, and Glutathione S-Transferase Mu3 in Oral Leukoplakia and Oral Squamous Cell Carcinoma with Deleterious Habits using Polymerase Chain Reaction. ( 28904918 )
2017
43
Serum metabolomics in oral leukoplakia and oral squamous cell carcinoma. ( 28862226 )
2017
44
Effects of Black Raspberry Extract and Berry Compounds on Repair of DNA Damage and Mutagenesis Induced by Chemical and Physical Agents in Human Oral Leukoplakia and Rat Oral Fibroblasts. ( 29068672 )
2017
45
Micronucleus Assay: An Early Diagnostic Tool to Assess Genotoxic Changes in Patients with Tobacco Use, Oral Leukoplakia and Oral Submucous Fibrosis. ( 29207828 )
2017
46
The Microbiome of Potentially Malignant Oral Leukoplakia Exhibits Enrichment for<i>Fusobacterium, Leptotrichia, Campylobacter</i>, and<i>Rothia</i>Species. ( 29250055 )
2017
47
Evaluation of Total and Lipid Bound Sialic Acid in Serum in Oral Leukoplakia. ( 28511503 )
2017
48
Quantitative prediction of oral cancer risk in patients with oral leukoplakia. ( 28545021 )
2017
49
New definition proposed for oral leukoplakia. ( 28928786 )
2017
50
Limited evidence for interventions to treat oral leukoplakia. ( 29075031 )
2017

Variations for Oral Leukoplakia

Expression for Oral Leukoplakia

Search GEO for disease gene expression data for Oral Leukoplakia.

Pathways for Oral Leukoplakia

Pathways related to Oral Leukoplakia according to GeneCards Suite gene sharing:

(show all 32)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.2 CCND1 CDKN2A PCNA TINF2 TP53
2
Show member pathways
12.75 CCND1 CDKN2A PCNA TP53
3
Show member pathways
12.74 CDKN2A PCNA TP53 TP63
4
Show member pathways
12.64 CCND1 CDKN2A PCNA TP53
5 12.62 CCND1 CDKN2A GSTM1 TP53
6
Show member pathways
12.54 CCND1 CDKN2A GSTM1 TP53
7
Show member pathways
12.47 CCND1 PCNA TP53 XRCC1
8
Show member pathways
12.31 CCND1 CDKN2A PCNA TP53
9 12.25 CCND1 CDKN2A TP53 TP63
10
Show member pathways
12.21 CCND1 PCNA TP53
11
Show member pathways
12.19 CCND1 CDKN2A TP53
12
Show member pathways
12.15 CCND1 CDKN2A TP53
13 12.09 CCND1 CDKN2A TP53
14 12.05 CCND1 CDKN2A PCNA TP53
15 12.03 CCND1 CDKN2A PCNA TP53
16 11.96 CCND1 CDKN2A TP53
17 11.86 PCNA TP53 TP63
18 11.78 CCND1 CDKN2A TP53
19 11.76 CCND1 CDKN2A TP53
20 11.73 CDKN2A PCNA TP53
21 11.64 CCND1 CDKN2A MKI67 PCNA TP53 TP63
22 11.63 CCND1 PCNA TP53
23 11.5 CCND1 CDKN2A TP53
24 11.47 CDKN2A GSTM1 TP53
25 11.22 CCND1 XRCC1
26 11.21 CCND1 CDKN2A TP53
27 11.14 CDKN2A TP53
28 11.08 PCNA TP53
29 11.08 CCND1 PCNA TP53
30 10.95 CDKN2A TP53
31 10.84 CCND1 PCNA TP53
32
Show member pathways
10.47 CDKN2A TP53 TP63

GO Terms for Oral Leukoplakia

Cellular components related to Oral Leukoplakia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.7 CCND1 CDKN2A PCNA TINF2 TP53 TP63
2 nuclear chromatin GO:0000790 9.43 TP53 TP63 XRCC1
3 nuclear chromosome, telomeric region GO:0000784 9.13 PCNA TINF2 XRCC1
4 nuclear body GO:0016604 8.92 MKI67 PCNA TINF2 TP53

Biological processes related to Oral Leukoplakia according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 cell cycle GO:0007049 9.76 CCND1 CDKN2A MKI67 TP53
2 cellular response to DNA damage stimulus GO:0006974 9.62 CCND1 PCNA TP53 XRCC1
3 base-excision repair GO:0006284 9.54 TP53 XRCC1
4 regulation of mitotic nuclear division GO:0007088 9.52 CCND1 MKI67
5 liver regeneration GO:0097421 9.51 CCND1 PCNA
6 protein tetramerization GO:0051262 9.49 TP53 TP63
7 cell aging GO:0007569 9.48 TP53 TP63
8 cell proliferation GO:0008283 9.46 MKI67 PCNA TP53 TP63
9 intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator GO:0042771 9.43 TP53 TP63
10 positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway GO:1900740 9.4 TP53 TP63
11 nucleotide-excision repair, DNA gap filling GO:0006297 9.37 PCNA XRCC1
12 replicative senescence GO:0090399 9.26 CDKN2A TP53
13 mitotic G1 DNA damage checkpoint GO:0031571 8.96 CCND1 TP53
14 negative regulation of protein ADP-ribosylation GO:0010836 8.62 TINF2 XRCC1

Molecular functions related to Oral Leukoplakia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA binding GO:0003677 9.63 CDKN2A MKI67 PCNA TINF2 TP53 TP63
2 disordered domain specific binding GO:0097718 9.32 CDKN2A TP53
3 histone acetyltransferase binding GO:0035035 9.26 PCNA TP53
4 damaged DNA binding GO:0003684 9.13 PCNA TP63 XRCC1
5 enzyme binding GO:0019899 9.02 CCND1 GSTM1 PCNA TP53 XRCC1

Sources for Oral Leukoplakia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....